Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOLOCORE-FU long-term follow-up after Holoclar transplantation
2015-001344-11Phase 4Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ex vivo reconstructed autologous human corneal epithelium containing stem cells in limbal stem cell deficiency (LSCD) and corneal fibrosis, sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Treatment-emergent adverse events, Treatment-related adverse events and 1 more. Started Jan 2018; status: completed.
02
Drugs
ex vivo reconstructed autologous human corneal epithelium containing stem cells
03
Conditions
limbal stem cell deficiency (LSCD)corneal fibrosis
Beyond the preview
Go deeper on 2015-001344-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001344-11.